Through research, Neuronicon has produced new knowledge that in the long term can lead to new types of medicine that can curb serious brain diseases, for example Alzheimer’s, and disabling brain damage, e.g. after suffering from a stroke.

Professor of biochemistry at the University of Aarhus, Anders Nykjær and Thomas Willnow from the University of Berlin are behind the research that underpins the company.

Neuronicon was founded in 2004, and CAPNOVA got involved in the very beginning offering risk capital and guidance.

In 2009, the company’s technology was sold to the pharmaceutical group Lundbeck, which has the necessary capacity to develop and commercialize new drug types based on Neuronicon’s research.

After the sale to Lundbeck, Neuronicon continued as an independent company, and in close cooperation with the university, the company found that the pioneering knowledge that the company produced could also be used in other diseases.

In connection with the sale to Lundbeck, CAPNOVA exited the company with a nice profit.